Edit Entry

Nadeem Khan, M.Sc., Ph.D.

Title(s):
Associate Professor of Radiology
EPR Center for Viable Systems, Department of Diagnostic Radiology
Dartmouth Medical School, Hanover, NH 03755

&

Investigator, Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756

Department(s):
Radiology

Education:
Ph.D. (Chemistry): 1998
M.Sc. (Chemistry): 1992
DICE (Diploma in Industrial & Computer Electronics): 1990
B.Sc. (Physics, Chemistry, Mathematics): 1989

Programs:
EPR Center at Dartmouth Medical School
Norris Cotton Cancer Center

Websites:
http://www.dartmouth.edu/~eprctr/

Contact Information:

Dartmouth Medical School
HB 7785 VAIL
Hanover NH 03755

Office: 640 Rubin, Norris Cotton Cancer Center
Phone: 603 653 3591
Fax: 603 650 1717
Email: nadeem.khan@dartmouth.edu


Professional Interests:

Application of EPR oximetry to assess and repeatedly follow tumor pO2 during therapies and use this vital information to optimize therapeutic outcome


Clinical application of EPR oximetry for diagnosis and prognosis of peripheral vascular diseases


Potential application of checkpoint inhibitors to increase malignant cell death during chemoradiation


Assessment of redox status and oxygen concentration using soluble probes such as nitroxides, spin trapping of free radicals etc

Grant Information:

ONGOING

RO1 CA120919 Khan (PI) 07/01/06 – 05/31/11
National Institutes of Health
Oxygen Guided Hypofractionated Radiotherapy for Gliomas
The overall goal is to demonstrate that the efficacy of the hypofractionated radiotherapy can be significantly enhanced by irradiating at times of optimal tumor oxygenation and that the use of hyperoxic therapies in conjunction with hypofractionated radiotherapy can be optimized by use of the information on oxygen levels in the tumors.


014519 Khan and Eastman (PI) 07/01/10 – 06/30/11
EISAI Inc. Andover, MA
Effect of a PARP inhibitor on tumor oxygenation and growth
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals DNA damage to repair proteins by synthesizing ADP-ribose polymers on the nuclear proteins. Consequently, inhibition of DNA repair by PARP inhibitors might enhance tumor cell death during chemotherapy and radiotherapy. The goal is to investigate the effect of a PARP inhibitor on the tissue oxygenation and growth of the gliomas when treated alone or in combination with chemotherapy.


30.058.287103 Khan and Eastman (PI) 02/01/11- 01/31/12
Norris Cotton Cancer Center, DHMC, Lebanon, NH
Oximetry-guided optimization of chemoradiation for gliomas
The overall goal is to enhance therapeutic outcome of glioma by efficaciously combining DNA damaging agents (gemcitabine and/or radiation) with SCH900776, an inhibitor of cell cycle checkpoint kinase 1 (Chk1). This will be achieved in part through an increase in the tumor pO2 (partial pressure of oxygen), which will further increase the efficacy of chemoradiation. The changes in the tumor pO2 are likely to provide an early indication of tumor response to therapy.


COMPLETED

R21DK072112 Khan (PI) 07/01/06 - 06/30/10
National Institutes of Health
Development of EPR and NIR Oximetry for Diabetic Foot
The major goal of this project is to develop and apply two emerging techniques - Electron Paramagnetic Resonance (EPR) and Near Infrared spectroscopy (NIR) for oximetry to characterize and follow tissue oxygenation in the diabetic foot and provide data that can improve the management of the serious and widespread complication of peripheral vascular disease.


R21 CA118069 Khan (PI) 07/01/06 - 06/30/10
National Institutes of Health
Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
The overall goal of this project is to demonstrate, under realistic conditions, that in vivo EPR oximetry can provide repetitive data on tumor oxygenation during the course of therapy and that this can be used to enhance therapeutic outcome.

P01 EB2180 Swartz(PI) 07/01/02 - 06/30/07
Measurement of pO2 in vivo and in vitro
The goal was to develop EPR oximetric material and the oximetry technique to investigate tissue pO2 in various pathologies including cancer.
Role: Co-Investigator


Biography:

POSITIONS AND EMPLOYMENT

1993-1996
Junior Research Fellow, North-Eastern Hill University, Shillong, India


1996-1997
Senior Research Fellow, North-Eastern Hill University, Shillong, India


1998-1999
Research Associate, University of Basel, Switzerland


Sept. 1999-2002
Postdoctoral Fellow, Dartmouth Medical School, Hanover, NH, USA


2007 – present
Investigator, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH


2002 - June, 2008
Research Assistant Professor, Dartmouth Medical School, NH, USA


July, 2009 - present
Research Associate Professor, Dartmouth Medical School, NH, USA


PROFESSIONAL MEMBERSHIPS

2003 -
Member, International Society on Oxygen Transport to Tissue (ISOTT)

2005 -
Member, International EPR Society (IES)


2007 -
Member, Radiation Research Society (RRS)


HONORS/AWARDS

1993
Junior Research Fellowship, Department of Atomic Energy, New Delhi, India


1996
Senior Research Fellowship, Department of Atomic Energy, New Delhi, India


1999
Best Poster Award, 32nd Annual International ESR Conference, University of York, U.K.


2003
Melvin H. Knisely Award by International Society on Oxygen Transport to Tissue (ISOTT), Rochester, New York


2005
Young Investigator Award, International Conference/Workshop on Electron Paramagnetic Resonance Spectroscopy and Imaging of Biological Systems, September 4-8, 2005, Ohio, USA


Selected Publications:

 

Hou H, Krishnamurthy Nemani V, Du G, Montano R, Song R, Gimi B, Swartz HM, Eastman A, Khan N
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.
Int J Cancer 2014 Aug 11;
PMID: 25111969

Swartz HM, Hou H, Khan N, Jarvis LA, Chen EY, Williams BB, Kuppusamy P
Advances in probes and methods for clinical EPR oximetry.
Adv Exp Med Biol 2014; 812:73-9
PMID: 24729217

Hou H, Li H, Dong R, Khan N, Swartz H
Real-time monitoring of ischemic and contralateral brain pO2 during stroke by variable length multisite resonators.
Magn Reson Imaging 2014 Jun; 32(5):563-9
PMID: 24629514

Swartz HM, Williams BB, Zaki BI, Hartford AC, Jarvis LA, Chen EY, Comi RJ, Ernstoff MS, Hou H, Khan N, Swarts SG, Flood AB, Kuppusamy P
Clinical EPR: unique opportunities and some challenges.
Acad Radiol 2014 Feb; 21(2):197-206
PMID: 24439333

Khan N, Mupparaju S, Hou H, Williams BB, Swartz H
Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen.
J Neurosci Methods 2012 Feb 15; 204(1):111-7
PMID: 22079559

Hou H, Dong R, Li H, Williams B, Lariviere JP, Hekmatyar SK, Kauppinen RA, Khan N, Swartz H
Dynamic changes in oxygenation of intracranial tumor and contralateral brain during tumor growth and carbogen breathing: a multisite EPR oximetry with implantable resonators.
J Magn Reson 2012 Jan; 214(1):22-8
PMID: 22033225

Hou H, Dong R, Lariviere JP, Mupparaju SP, Swartz HM, Khan N
Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry.
J Radiat Res 2011; 52(5):568-74
PMID: 21799293

Khan N, Blinco JP, Bottle SE, Hosokawa K, Swartz HM, Micallef AS
The evaluation of new and isotopically labeled isoindoline nitroxides and an azaphenalene nitroxide for EPR oximetry.
J Magn Reson 2011 Aug; 211(2):170-7
PMID: 21665499

Mupparaju S, Hou H, Lariviere JP, Swartz H, Jounaidi Y, Khan N
Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
Oncol Rep 2011 Jul; 26(1):281-6
PMID: 21503586

Mupparaju S, Hou H, Lariviere JP, Swartz HM, Khan N
Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.
Adv Exp Med Biol 2011; 701:107-13
PMID: 21445776